Publisher Correction: Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

por Isaac V. Cohen, Tigran Makunts, Rabia Atayee, Ruben Abagyan
Publicado 2017

Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database

por Isaac V. Cohen, Tigran Makunts, Ruben Abagyan, Kelan Thomas
Publicado 2021

Population scale data reveals the antidepressant effects of ketamine and other therapeutics approved for non-psychiatric indications

por Isaac V. Cohen, Tigran Makunts, Rabia Atayee, Ruben Abagyan
Publicado 2017

Elucidation of transient protein-protein interactions within carrier protein-dependent biosynthesis

por Thomas G. Bartholow, Terra Sztain, Ashay Patel, D. John Lee, Megan A. Young, Ruben Abagyan, Michael D. Burkart
Publicado 2021

Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data

por Tigran Makunts, Ila M. Saunders, Isaac V. Cohen, Mengxing Li, Talar Moumedjian, Masara A. Issa, Keith Burkhart, Peter Lee, Sandip Pravin Patel, Ruben Abagyan
Publicado 2021

Structural basis of ligand interaction with atypical chemokine receptor 3

por Martin Gustavsson, Liwen Wang, Noortje van Gils, Bryan S. Stephens, Penglie Zhang, Thomas J. Schall, Sichun Yang, Ruben Abagyan, Mark R. Chance, Irina Kufareva, Tracy M. Handel
Publicado 2017

An electrostatic mechanism for Ca2+-mediated regulation of gap junction channels

por Brad C. Bennett, Michael D. Purdy, Kent A. Baker, Chayan Acharya, William E. McIntire, Raymond C. Stevens, Qinghai Zhang, Andrew L. Harris, Ruben Abagyan, Mark Yeager
Publicado 2016

The anthelmintic praziquantel is a human serotoninergic G-protein-coupled receptor ligand

por John D. Chan, Pauline M. Cupit, Gihan S. Gunaratne, John D. McCorvy, Yang Yang, Kristen Stoltz, Thomas R. Webb, Peter I. Dosa, Bryan L. Roth, Ruben Abagyan, Charles Cunningham, Jonathan S. Marchant
Publicado 2017

Crowdsourced identification of multi-target kinase inhibitors for RET- and TAU- based disease: The Multi-Targeting Drug DREAM Challenge.

por Zhaoping Xiong, Minji Jeon, Robert J Allaway, Jaewoo Kang, Donghyeon Park, Jinhyuk Lee, Hwisang Jeon, Miyoung Ko, Hualiang Jiang, Mingyue Zheng, Aik Choon Tan, Xindi Guo, Multi-Targeting Drug DREAM Challenge Community, Kristen K Dang, Alex Tropsha, Chana Hecht, Tirtha K Das, Heather A Carlson, Ruben Abagyan, Justin Guinney, Avner Schlessinger, Ross Cagan
Publicado 2021